Lombard Medical and MicroPort Finalize Strategic Partnership in China

April 3, 2017—Lombard Medical, Inc. and MicroPort Scientific Corporation announced that the companies have finalized the definitive agreements to their strategic partnership first announced in December 2016.

The partnership will allow Lombard to accelerate commercialization in China and other global markets for its abdominal aortic aneurysm (AAA) product portfolio, including the Aorfix and Altura devices. The Aorfix stent graft has global approvals to treat AAAs with aortic neck angles up to 90º. The Altura stent graft has an ultra-low-profile delivery system that offers an easy-to-use and predictable treatment option for standard AAA anatomy.

According to the companies, Lombard and MicroPort have entered into a component supply manufacturing agreement whereby certain components for the Aorfix and Altura product lines will be manufactured by MicroPort in its facilities in Shanghai. It is anticipated that MicroPort will begin providing components to Lombard in the second half of 2017.

MicroPort has the exclusive marketing rights for the Lombard product portfolio in China and Brazil, as well as a technology license to manufacture the products for the China market. MicroPort expects to launch Aorfix in China after gaining China Food and Drug Administration approval, which is anticipated in the second half of 2018, advised the companies.